One To Watch

Bicycle Therapeutics

Company Overview

A Cambridge, UK-based clinical-stage biotech pioneering a proprietary class of bicyclic peptide (Bicycle) medicines targeting oncology and other high-unmet-need diseases underserved by conventional therapeutics. Bicycle Therapeutics develops a novel modality — constrained bicyclic peptides — that combines the target selectivity of biologics with the tissue penetration and manufacturing advantages of small molecules. The company advances both wholly-owned oncology programs and partnered discovery efforts spanning immuno-oncology, respiratory, cardiovascular, ophthalmology, and anti-infective indications.

Headquarters and Global Presence

Bicycle Therapeutics is headquartered in Cambridge, UK, with significant commercial and operational presence in the United States. The company is listed on the Nasdaq Global Select Market as an American Depositary Share, giving it a dual Anglo-American identity reflected in its investor base and clinical trial footprint.

Founding and History

Bicycle Therapeutics was founded in 2009 to develop bicyclic peptide medicines based on research originating from phage-display-enabled peptide discovery. The company has since advanced from a discovery-stage platform into a clinical-stage pipeline with multiple assets in human trials. Key milestones include Nasdaq listing, expansion of multiple large-cap pharma partnerships, and a pivotal R&D day hosted in New York in June 2024 that showcased its maturing pipeline to institutional investors.

Therapy Areas and Focus

Oncology is the primary focus, with Bicycle-toxin conjugates (BTCs) targeting tumor-associated antigens including Nectin-4 and EphA2 in solid tumors representing high unmet clinical need. Beyond oncology, the company has active collaborations addressing respiratory, cardiovascular, and metabolic diseases through its AstraZeneca alliance, and ophthalmology through its ThromboGenics partnership. Earlier programs explored hemophilia and sickle cell disease in partnership with Bioverativ, illustrating the platform's broad applicability.

Technology Platforms and Modalities

The proprietary Bicycle platform uses phage display to identify bicyclic peptides — small, structurally constrained molecules formed by linking two peptide loops to a molecular scaffold. This architecture confers high target affinity and selectivity while retaining the pharmacokinetic tunability and synthetic accessibility typical of small molecules. The platform supports multiple modality formats, including Bicycle-toxin conjugates (BTCs) for targeted payload delivery, immuno-oncology T-cell engagers (Bicycle TICA), and radioligand therapy (RLT) vehicles in collaboration with Eckert & Ziegler. The diversity of output formats from a single discovery engine is a core competitive advantage.

Key Pipeline and Programs

Nuzefatide pevedotin (formerly BT5528) is a BTC targeting EphA2, a receptor tyrosine kinase overexpressed in multiple solid tumors including bladder, lung, and ovarian cancers. The asset was the subject of updated clinical and preclinical data presented at the AACR Annual Meeting in April 2026, signaling continued advancement of the EphA2 program. BT8009 is a second-generation BTC targeting Nectin-4, a cell-adhesion molecule highly expressed in urothelial carcinoma and other solid tumors. BT8009 generated positive interim Phase I results from its Phase I/II trial, driving a 24.5% single-day share price gain when data were disclosed in mid-2024; the asset continues to progress through Phase I/II evaluation. THR-149, developed under the ophthalmology alliance with ThromboGenics, entered Phase I clinical evaluation with a milestone payment triggered upon study initiation, extending Bicycle's clinical reach beyond oncology.

Recent Developments

In April 2026, Bicycle presented updated data on nuzefatide pevedotin and its broader EphA2 pipeline at the AACR Annual Meeting, reinforcing the clinical trajectory of its lead oncology program. In February 2026, the company announced leadership transitions to position itself for its next phase of innovation. In February 2025, Eckert & Ziegler entered a comprehensive strategic partnership with Bicycle to advance radioligand therapy applications of the Bicycle platform, adding a radiopharmaceutical dimension to the pipeline.

Key Personnel

Kevin Lee serves as Chief Executive Officer, appointed to lead the company through its clinical and commercial maturation phase. Maria Koehler serves as Chief Medical Officer, bringing oncology development experience from her prior role as Vice President in oncology at Pfizer. Santiago Arroyo serves as Chief Development Officer, effective March 31, 2024, adding operational development expertise to the senior leadership team.

Strategic Partnerships

Bicycle holds a potentially $1.7 billion strategic collaboration with Bayer and a separate licensing deal of equivalent value with Novartis, both disclosed in June 2024 and anchoring the company's near-term financial profile. Roche's Genentech subsidiary partnered with Bicycle on immuno-oncology discovery, while AstraZeneca expanded its multi-target collaboration to include additional respiratory and cardio-metabolic disease programs. Eckert & Ziegler's 2025 radioligand partnership and the longstanding ThromboGenics ophthalmology alliance further diversify the partnered portfolio.

FAQ Section

Bicycle has secured large-cap pharma alliances with Bayer, Novartis, Genentech/Roche, and AstraZeneca, with individual deals carrying up to $1.7 billion in potential milestone value. These collaborations fund platform exploration across immuno-oncology, respiratory, cardiovascular, and metabolic indications, while Bicycle retains ownership of its core wholly-owned oncology assets like nuzefatide pevedotin and BT8009. The dual strategy — partnered discovery plus proprietary clinical programs — diversifies risk and funds internal development without dilutive equity raises.

Bicyclic peptides are structurally constrained molecules formed by anchoring two peptide loops to a central scaffold, a geometry that sharply reduces conformational flexibility and increases binding affinity and selectivity at the target. Unlike linear peptides, Bicycle molecules resist proteolytic degradation and can be tuned pharmacokinetically, enabling tissue penetration profiles more similar to small molecules than to antibodies. This positions them as a versatile intermediate modality capable of reaching intracellular or architecturally complex extracellular targets that are inaccessible to larger biologics.

Bicycle-toxin conjugates use a small bicyclic peptide targeting moiety in place of a large monoclonal antibody, resulting in a significantly smaller overall molecular size that may facilitate deeper tumor penetration and a faster clearance profile that reduces systemic toxin exposure. The synthetic manufacturability of the Bicycle scaffold also offers potential cost and process advantages over antibody-based conjugates. BT8009, targeting Nectin-4, generated clinically meaningful interim Phase I/II data that suggest the approach can deliver cytotoxic payload to tumors with a differentiated tolerability profile.

Nuzefatide pevedotin is a BTC targeting EphA2, a receptor tyrosine kinase overexpressed across multiple solid tumors including bladder, non-small cell lung, and ovarian cancers. The asset was highlighted at the AACR Annual Meeting in April 2026, with updated clinical and preclinical data presented, indicating the program remains in active Phase I/II development. EphA2 is an attractive target because its expression correlates with tumor invasiveness and poor prognosis, and it has historically lacked effective targeted therapies.

Oncology is the center of gravity, with BTCs and immuno-oncology T-cell engagers targeting solid tumor antigens such as Nectin-4 and EphA2. Beyond cancer, the platform's versatility is demonstrated by active programs in ophthalmology (THR-149 with ThromboGenics), respiratory and cardio-metabolic diseases (AstraZeneca), and radioligand therapy (Eckert & Ziegler). The breadth reflects a deliberate strategy of demonstrating platform applicability across multiple biology classes while keeping the internal pipeline tightly focused on oncology where the clinical value proposition is clearest.

Bicycle is a clinical-stage company with multiple assets in Phase I/II trials, most prominently BT8009 and nuzefatide pevedotin in oncology. The June 2024 R&D day marked a transition toward greater clinical transparency and institutional investor engagement, signaling the company's readiness to move assets toward later-stage pivotal decisions. Leadership transitions announced in February 2026 were framed as positioning the company for its next phase of innovation, suggesting internal preparation for Phase II/III advancement.

Key watchpoints include:

Phase I/II data readouts for BT8009 (Nectin-4) and nuzefatide pevedotin (EphA2), which will define the path to pivotal trials
Milestone triggers across the Bayer, Novartis, and Genentech partnerships, each carrying up to $1.7 billion in headline value
Progress of the Eckert & Ziegler radioligand partnership as a potential new clinical modality
Leadership execution risk following the February 2026 transition, particularly for the Chief Development Officer role driving clinical operations
Platform validation risk: commercial success depends on at least one BTC demonstrating Phase II/III efficacy in competitive tumor indications already served by approved ADCs

Want to Update your Company's Profile?